Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2024 | Story Leonie Bolleurs | Photo SUPPLIED
Dr Lucas Erasmus
Dr Lucas Erasmus, Junior Researcher in the Department of Physics, has just returned from Belgium where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

“I like taking what I have learned from literature and going to the laboratory to test it. Sometimes the results surprise me, leading to additional experiments or refining. This process could continue for several months and even years, with me slowly building the puzzle. And finally, one day, all the pieces come together, and everything becomes very clear to me as a physicist. And if I am lucky, I will have the privilege of knowing a secret about nature that nobody else has known up to this point. However, as an innovator, I am tasked with using this new knowledge to develop ways to manipulate nature to deliver a helpful device.”

These are the thoughts of Dr Lucas Erasmus, Junior Researcher in the Department of Physics at the University of the Free State (UFS), who has just returned from Ghent, Belgium, where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

The research project is part of a bilateral collaboration between the Department of Physics at the UFS and the Department of Solid State Sciences at Ghent University. In this study, the strengths, experience, and resources of both research groups – experienced in developing luminescent materials for various applications – are used to ensure a stronger final product. To meet the requirements stipulated in the cooperation agreement between the two institutions for the joint supervision and certification of Dr Erasmus’ doctoral studies, research was conducted both at the UFS and at Ghent University.

Dr Erasmus’ research is significant in the light of rising energy prices, energy scarcity, and the pursuit of a carbon-free society, where there are strong incentives to develop new and renewable energy sources.

Combining windows and solar cells increase their relevancy in many applications

He says that although solar panels play an essential role in renewable energy – since they provide a route to directly convert solar radiation into electricity – there are limitations to installing conventional panels, which are bulky, rigid, and opaque. He believes that combining windows and solar cells could increase their relevance in the built environment, agricultural sector, and modern consumer electronics.

Explaining about the luminescent solar concentrator (LSC) in his study, he states that it is a device used as a large-area solar radiation collector that converts and emits radiation. The emitted radiation is directed to photovoltaic cells located in the small side area of the device. According to him, a basic LSC consists of a transparent waveguide with an embedded luminescent material and a strategically placed photovoltaic cell on the edge.

Dr Erasmus continues, “The large area of the waveguide collects a portion of the solar radiation, while the luminescent material absorbs the energy and downshifts it to longer wavelengths. Internal reflection directs the emitted photons towards smaller areas on the sides where the photovoltaic cells are used to convert the concentrated light into electricity.”

In his view, creating a large and efficient LSC is a challenging endeavour that requires an in-depth study of multiple domains. “This includes developing and optimising the luminescent material, studying its behaviour and the characteristics of the waveguide, and finally adding these two components and developing, characterising, and simulating the hybrid device,” he remarks.

“While the current prototype we have developed delivers good results, it is still far from perfect and not commercially viable,” he says, stating that this study could, however, serve as a guide for future researchers interested in developing LCSs. Dr Erasmus believes the underlying science behind the results contributes to a general understanding of the materials, making this study valuable to other fields and contributing to the larger body of science. At the end of the study, he also makes some recommendations for future research in this field. 

Study a reflection of theoretical knowledge and a practical system

The public defence consisted of both an internal and an external defence. The internal defence took place in January at the UFS between Dr Erasmus and the examination committee. The external defence occurred at Ghent University and was also open to the broader public. Also present at this event in Belgium were colleagues from the UFS – Prof David Motaung, an examiner; Prof Koos Terblans, co-supervisor; and Prof Hendrik Swart, supervisor for the PhD thesis.

Dr Erasmus’ experience of the oral examination was that the examiners were primarily positive in their critique but also thorough in their questioning. According to him, some of their remarks pointed out that they were impressed with the meticulous planning, execution, and interpretation of the experimental results and that the researchers involved ensured that any parameter that might have influenced the device was maximised. “Moreover, they liked the fact that I went all the way from theoretical knowledge to a practical system. The examiners also noted that the study compares well with the current state-of-the-art research in the field,” adds Dr Erasmus.

He says that having the public defence in Belgium was a once-in-a-lifetime experience, allowing him to interact and deliberate directly with the examiners and communicate their findings and conclusions to the broader public. Dr Erasmus hopes that this will lead to stronger collaboration and better public sentiment toward spending funding for scientific projects.

For future steps, he states, the research group involved in the project plans to continue this research by further increasing the device's efficiency. “To this end, we have already developed another luminescent material that can address some of the challenges we encountered while developing the first prototype device. This forms part of the work that Johané Odendaal is doing in her master’s degree, of which I am a co-supervisor. We also plan to enlarge the scope of our research to consider the challenges that are currently hampering the next generation of photovoltaic cells and to find ways in which we could address these issues,” comments Dr Erasmus.

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept